Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease

Europace

Volumn 13, Issue 12, 2011, Pages 1781-1788

  Omahony, Constantinos ^a   Coats, Caroline ^a   Cardona, Monserrat ^a   Garcia, Alfredo ^a   Calcagnino, Margherita ^a   Murphy, Elaine ^b   Lachmann, Robin ^b   Mehta, Atul ^c   Hughes, Derralynn ^c   Elliott, Perry M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Anderson Fabry disease; Atrio ventricular node dysfunction; Cardiac pacing; Sinus node dysfunction; Sudden cardiac death

Indexed keywords

ADULT; AGED; ARTICLE; BRADYCARDIA; COHORT ANALYSIS; FABRY DISEASE; FEMALE; FOLLOW UP; HEART PACING; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE DISEASE; OBSERVATIONAL STUDY; PACEMAKER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QRS COMPLEX; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SINUS NODE DISEASE;

ADULT; BRADYCARDIA; CARDIAC PACING, ARTIFICIAL; COHORT STUDIES; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART CONDUCTION SYSTEM; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 81855211030     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur267     Document Type: Article

References (31)

1. Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U et al. Fabry disease: a review of current management strategies. QJM 2010;103:641-59.
2. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35. (Pubitemid 47343855)
3. Lobo T, Morgan J, Bjorksten A, Nicholls K, Grigg L, Centra E et al. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J 2008; 38:407-14. (Pubitemid 351871981)
4. Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardio-graphic abnormalities in Fabryaposs disease. Am Heart J 1977;93:699-705. (Pubitemid 8201083)
5. Namdar M, Kampmann C, Steffel J, Walder D, Holzmeister J, Luscher TF et al. PQ interval in patients with Fabry disease. Am J Cardiol 2010;105:753-6.
6. Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 2003;63:46-52. (Pubitemid 36949894)
7. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005;96:842-6. (Pubitemid 41319722)
8. Sheth KJ, Thomas JP Jr. Electrocardiograms in Fabryaposs disease. J Electrocardiol 1982; 15:153-6.
9. Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 2010;31:1088-97.
10. Frustaci A, Chimenti C. Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation 2007;116:e350-1. (Pubitemid 47417570)
11. Ikari Y, Kuwako K, Yamaguchi T. Fabryaposs disease with complete atrioventricular block: histological evidence of involvement of the conduction system. Br Heart J 1992;68:323-5.
12. Beck M. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl 2006;95:43-6. (Pubitemid 43739094)
13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiographyaposs Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. (Pubitemid 41821197)
14. Teichholz LE, Cohen MV, Sonnenblick EH, Gorlin R. Study of left ventricular geometry and function by B-scan ultrasonography in patients with and without asy-nergy. N Engl J Med 1974;291:1220-6.
15. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. 1st edn. New York: Springer; 2001.
16. Altman DG. Practical Statistics for Medical Research. 1st edn. London: Chapman and Hall/CRC; 1991.
17. Vardas P, Auricchio A, Merino JL. The EHRA White Book 2011: The current status of cardiac electrophysiology in ESC member countries. 2011. www.escardio.org/EHRA
18. Sheppard MN, Cane P, Florio R, Kavantzas N, Close L, Shah J et al. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol 2010;19:293-301.
19. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007;93:528-35. (Pubitemid 46631530)
20. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacoki-netic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-22. (Pubitemid 32202764)
21. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabryaposs disease. N Engl J Med 2001;345:9-16. (Pubitemid 32634266)
22. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 2003;26:617-27. (Pubitemid 38008966)
23. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285:2743-9. (Pubitemid 32525371)
24. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94:153-8. (Pubitemid 351211719)
25. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabryaposs cardiomyopathy. Am J Cardiol 2006;97:1515-8.
26. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119: 524-9.
27. Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabryaposs disease with a short PR interval. Am J Cardiol 1994;74:203-4. (Pubitemid 24219320)
28. Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J 2010;31:67-76.
29. Carter N, Milroy CM, Shepherd RT. Sudden death in elderly women with Fabryaposs disease. Am J Forensic Med Pathol 1995;16:21-6.
30. Sivaloganathan S. Fabryaposs disease-a rare cause of sudden death. Med Sci Law 1992;32:263-6.
31. Eckart RE, Kinney KG, Belnap CM, Le TD. Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabryaposs disease. Review of cardiovascular manifestations. Cardiology 2000;94:208-12. (Pubitemid 32250152)